- Home
- Products
Brentuximab Vedotin
Brentuximab Vedotin
- Generic Name: Brentuximab Vedotin
- Dosage Form & Strength: 50 mg
- Packing: Single-Use Vial
Brentuximab Vedotin is a CD30-directed antibody-drug conjugate used in the treatment of specific types of lymphoma. It is FDA-approved and indicated for:
- Treatment of Hodgkin lymphoma in patients who have failed autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in non-ASCT candidates.
- Systemic anaplastic large cell lymphoma (sALCL) following failure of at least one prior multi-agent chemotherapy regimen.
- Previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.
Concurrent use of Brentuximab Vedotin with bleomycin is contraindicated due to increased risk of pulmonary toxicity.
Patients should be monitored for peripheral neuropathy symptoms including numbness, tingling, pain, or weakness.
Complete blood counts must be assessed before each dose, especially in patients with Grade 3 or 4 neutropenia.
Vigilant monitoring is required to detect signs of bacterial, fungal, or viral infections during treatment.
Brentuximab Vedotin may cause fetal harm; pregnancy should be avoided, and breastfeeding is not advised during therapy.
To access Brentuximab Vedotin (Adcetris) through GlobalRareMeds, the following documentation is required:
- Valid prescription from a licensed medical practitioner
- Diagnostic reports of the patient
- Government-issued patient ID
Order Confirmation:
Orders will be confirmed only after submission of the valid prescription and, where applicable, an import permit.
Brentuximab Vedotin is a regulated prescription-only medication, available under named-patient import models in India and various countries.
GlobalRareMeds sources Brentuximab Vedotin from certified global distributors across the USA, Europe, Canada, and Australia.
Our fulfillment center in Ambernath, Thane District, ensures regulatory-compliant storage, pharmacist-verified dispatch, and end-to-end delivery across:
- India and SAARC nations (Bangladesh, Nepal, Bhutan, Sri Lanka, Maldives, Afghanistan, Pakistan)
- Other global locations as per compliance
For Pricing and Availability:
📧 Email: info@globalraremeds.com
📞 Call/WhatsApp: +91-99675 15602
Q. What is the generic name of Adcetris?
A. The generic name is Brentuximab Vedotin.
Q. What is the dosage form available?
A. Brentuximab Vedotin is available as a 50 mg single-use vial for intravenous administration.
Q. How should Brentuximab be stored?
A. Store at 2–8°C (36–46°F) in the original carton. Protect from light and keep out of reach of children.
Q. Are generics or biosimilars available for Brentuximab?
A. No generic or biosimilar versions of Brentuximab Vedotin are currently approved globally.
Q. What are the common side effects?
A. Common adverse effects include fatigue, fever, nausea, peripheral neuropathy, diarrhea, constipation, low blood counts, cough, and skin rash.
Q. What are the recent clinical developments for Adcetris?
A. The HD21 study supports use of a new combination (BrECADD) to reduce side effects in cHL treatment. The ECHELON-3 trial showed improved survival in relapsed/refractory DLBCL when combined with lenalidomide and rituximab.
Q. Has Adcetris been explored in solid tumors?
A. Yes, recent immunotherapy combinations involving Adcetris have shown promise in preclinical studies for solid tumors.
Q. Is Adcetris approved for pediatric use?
A. Yes, it is approved for pediatric patients aged 2 years and older with high-risk classical Hodgkin lymphoma.
Q. What is the latest regulatory update?
A. The European Commission approved Adcetris in combination with chemotherapy for newly diagnosed CD30+ stage III cHL, based on ECHELON-1 trial results.
Q. Is Brentuximab available in Asia?
A. Yes, Brentuximab Vedotin is available across Asia including India, Bangladesh, Pakistan, Nepal, Sri Lanka, Maldives, Bhutan, and Afghanistan.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
